📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Alembic Pharmaceuticals Incorporates New Subsidiary in Thailand for Market Expansion
Alembic Pharmaceuticals Limited has successfully incorporated a new subsidiary, Alembic Pharmaceuticals (Thailand) Co., Ltd., in Thailand. The company holds a 99.99% stake in the new entity, which has an initial share capital of 3,000,000 Baht. This strategic move is designed to explore new business opportunities and facilitate the promotion, sale, and distribution of pharmaceutical products within the Thai geography. While the subsidiary has yet to commence operations, it marks a clear intent to strengthen the company's international presence.
Key Highlights
Incorporation of Alembic Pharmaceuticals (Thailand) Co., Ltd. as a 99.99% owned subsidiary
Initial share capital of 3,000,000 Baht divided into 300,000 shares of 10 Baht each
Primary objective is to promote and distribute pharmaceutical products in the Thailand market
Current turnover is nil as the entity is newly incorporated and yet to start operations
Investment is made in cash for the acquisition of share capital
💼 Action for Investors
Investors should monitor the company's progress in the Southeast Asian market as this expansion could provide a new revenue stream. No immediate action is required as the financial impact will only be visible once operations commence.
Alembic Pharma Reports First US Prescription Sale of Branded Antibiotic Pivya®
Alembic Pharmaceuticals has achieved its first prescription sale of Pivya® in the US, marking its official entry into the US branded specialty market. Pivya® is a first-line antibiotic for uncomplicated urinary tract infections (uUTIs), a therapeutic category with approximately 30 million prescriptions annually in the US. This launch follows a strategic acquisition and represents a shift from a purely generic-focused model to a branded specialty portfolio in the US. The company has established an initial sales footprint and plans a phased expansion of its field force to drive growth.
Key Highlights
First prescription sale of Pivya® in the US, marking Alembic's first branded product launch in the region.
Targets the uUTI market in the US, which accounts for approximately 30 million prescriptions annually.
Marketed through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of the company.
Represents a strategic shift to build a branded specialty portfolio alongside its established generics business.
Initial sales footprint established across key US territories with plans for phased field force expansion.
💼 Action for Investors
Investors should monitor the prescription growth and market penetration of Pivya® as it represents a higher-margin opportunity compared to traditional generics. This strategic entry into the US branded market could be a long-term value driver for the stock.
Alembic Pharma Proposes Appointment of Rajkumar Baheti with ₹2.5 Cr Annual Professional Fees
Alembic Pharmaceuticals has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Rajkumar Baheti as a Non-Executive Non-Independent Director effective April 1, 2026. The company is also seeking a special resolution to pay him professional fees up to ₹2.50 Crores per annum for one year, which is in addition to standard sitting fees. This fee exceeds the typical monetary thresholds prescribed under the Companies Act, requiring specific member approval. The e-voting period for these resolutions is scheduled from March 2 to March 31, 2026.
Key Highlights
Proposed appointment of Mr. Rajkumar Baheti as Non-Executive Non-Independent Director starting April 1, 2026
Approval sought for professional fees up to ₹2.50 Crores per annum plus applicable taxes
The professional fee arrangement is proposed for a period of one year
Remote e-voting period set from March 2, 2026, to March 31, 2026
The professional fee resolution is a Special Resolution, requiring 75% majority for approval
💼 Action for Investors
Investors should review the justification for the ₹2.5 crore professional fee in the explanatory statement and cast their votes by March 31, 2026.
Alembic Pharma Receives USFDA Approval for Lamotrigine Tablets; $27M Market Size
Alembic Pharmaceuticals has received final USFDA approval for Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, 100 mg, and 200 mg strengths. The product is a generic version of GSK's Lamictal ODT and is used to treat seizures and bipolar I disorder. The addressable market for this product is estimated at US$ 27 million for the 12 months ending December 2025. This approval brings Alembic's total USFDA ANDA approvals to 235, including 216 final approvals.
Key Highlights
Received final USFDA approval for Lamotrigine Orally Disintegrating Tablets USP in four strengths.
Estimated market size for the product is US$ 27 million for the 12 months ending December 2025.
Product is therapeutically equivalent to GlaxoSmithKline's Lamictal ODT.
Cumulative USFDA ANDA approvals now stand at 235, with 216 final and 19 tentative approvals.
💼 Action for Investors
This approval adds to Alembic's growing US generics portfolio and demonstrates steady regulatory execution. Investors should monitor the company's ability to monetize its 216 final approvals in the competitive US market.
Alembic Pharma Completes USFDA Inspection at Karakhadi Facility with 2 Observations
Alembic Pharmaceuticals has concluded an unannounced USFDA inspection at its Karakhadi Injectable Facility (F-3). The inspection, which took place from February 9 to February 18, 2026, resulted in two observations. Crucially, the company stated that none of the observations are related to data integrity, which is often a major concern for regulators. The company intends to respond to these observations within the required timeframe to maintain its compliance status.
Key Highlights
USFDA conducted an unannounced cGMP inspection at the Karakhadi (F-3) injectable facility.
The inspection spanned 10 days from February 9th to February 18th, 2026.
The audit concluded with 2 observations, none of which pertain to data integrity.
The company will submit a formal response to the observations within the stipulated time.
💼 Action for Investors
Investors should monitor for further updates regarding the nature of the observations and the subsequent issuance of an Establishment Inspection Report (EIR). The absence of data integrity issues is a positive sign, suggesting the observations may be procedural.
Alembic Pharma Q3 FY26: Revenue Up 11% to ₹1,876 Cr; US Branded Launch Pivya Set for Q4
Alembic Pharmaceuticals reported a steady Q3 FY26 with revenue growing 11% YoY to ₹1,876 crores, driven by a robust 36% growth in Rest of World (ROW) markets and 6% growth in the US. EBITDA (pre-R&D) increased 20% to ₹464 crores, reflecting improved operating leverage despite gross margins moderating to 72% due to pricing pressures. A significant strategic milestone is the upcoming Q4 launch of 'Pivya,' the company's first branded product in the US market. While domestic growth remained tepid at 6%, management expects to return to market growth rates by Q1 FY27.
Key Highlights
Revenue grew 11% YoY to ₹1,876 crores, with EBITDA (pre-R&D) rising 20% to ₹464 crores.
US business grew 6% YoY with 7 new ANDA approvals and a strategic branded launch (Pivya) planned for Q4 FY26.
ROW markets delivered strong performance with 36% YoY growth, offsetting pricing pressures in API and US generics.
R&D spend increased 33% to ₹165 crores (9% of revenue) to support complex injectables and peptides.
One-time exceptional provision of ₹42 crores recognized due to New Labour Code employee benefit changes.
💼 Action for Investors
Investors should watch for the successful commercialization of 'Pivya' in the US, as it marks a shift toward higher-margin branded business. Monitor the domestic segment's recovery in FY27 to see if it aligns with management's market-growth targets.
Alembic Pharma Receives USFDA Final Approval for Parkinson's Disease Tablets
Alembic Pharmaceuticals has received final USFDA approval for its ANDA for Carbidopa, Levodopa, and Entacapone Tablets in six different strengths. These tablets are indicated for the treatment of Parkinson's disease and are therapeutically equivalent to the reference drug Stalevo. This approval marks a significant addition to the company's US portfolio, which now includes a cumulative total of 234 ANDA approvals. The company continues to leverage its vertically integrated R&D to expand its global generic footprint.
Key Highlights
Received final USFDA approval for Carbidopa, Levodopa, and Entacapone Tablets in 6 dosage strengths.
The product is a generic version of Orion Corporation's Stalevo Tablets used for Parkinson's disease.
Alembic now has a cumulative total of 234 ANDA approvals, consisting of 214 final and 20 tentative approvals.
The company maintains a strong domestic presence with a field force of over 5,500 personnel.
💼 Action for Investors
Investors should monitor the commercial launch and market share gains for this product in the US. The steady stream of ANDA approvals reinforces Alembic's long-term growth strategy in the generic pharmaceutical space.
Alembic Pharma Q3 Revenue Up 11% to ₹1,876 Cr; PAT Dips to ₹133 Cr on Exceptional Costs
Alembic Pharmaceuticals reported a 10.8% YoY growth in consolidated revenue to ₹1,876.31 crore for Q3 FY26. Net profit after non-controlling interests saw a slight decline of 3.9% YoY to ₹132.97 crore, primarily due to a one-time exceptional charge of ₹42.23 crore related to the implementation of new Labour Codes. Despite the profit dip, operating margins remained resilient at 16.42%, up from 16.00% in the previous year. The company also announced that Mr. Rajkumar Baheti will transition to a Non-Executive Director role effective April 2026.
Key Highlights
Consolidated Revenue from Operations increased 10.8% YoY to ₹1,876.31 crore.
Net Profit (PAT) stood at ₹132.97 crore, impacted by a ₹42.23 crore exceptional provision for employee benefits.
Operating Margin improved to 16.42% in Q3 FY26 compared to 16.00% in Q3 FY25.
Debt-Equity ratio remains stable and healthy at 0.25x.
Mr. Rajkumar Baheti appointed as Non-Executive Director effective April 1, 2026, following his tenure as Executive Director.
💼 Action for Investors
The underlying business performance remains steady with healthy revenue growth; the profit decline is largely attributed to a non-recurring regulatory provision. Investors should focus on the company's margin sustainability and growth in its core pharmaceutical segments.
Alembic Pharma Q3 FY26 Revenue Up 11% to INR 18.76 Bn; Ex-US Generics Surges 36%
Alembic Pharmaceuticals reported a steady Q3 FY26 with revenue growing 11% YoY to INR 18.76 billion, driven largely by a 36% surge in Ex-US Generics. While EBITDA grew 14% to INR 3.08 billion, the bottom line was impacted by a one-time exceptional loss of INR 0.42 billion, leading to a slight 4% dip in PAT to INR 1.33 billion. The India Branded and US Generics segments showed moderate growth of 6% each, while the Animal Health division performed strongly with 22% growth. R&D investments remained significant at 9% of revenue, supporting a pipeline of 270 ANDA filings.
Key Highlights
Total Revenue increased 11% YoY to INR 18.76 billion in Q3 FY26.
Ex-US Generics revenue reached an all-time high of INR 4.06 billion, growing 36% YoY.
EBITDA margins stood at 16%, with EBITDA growing 14% YoY to INR 3.08 billion.
India Branded Business grew 6% to INR 6.52 billion, maintaining a 21st rank in the Indian Pharmaceutical Market.
R&D expenditure increased to INR 1.65 billion, representing 9% of total revenue.
💼 Action for Investors
Investors should take note of the strong momentum in Ex-US Generics and Animal Health, which are effectively diversifying the company's revenue streams. The core India and US businesses remain stable, though the impact of one-time exceptional items on the net profit should be monitored.
Alembic Pharma Q3 FY26 Revenue Up 11% to ₹1,876 Cr; Ex-US Generics Surge 36%
Alembic Pharmaceuticals reported a steady 11% YoY revenue growth for Q3 FY26, reaching ₹1,876 Cr, driven by a robust 36% surge in Ex-US international generics. EBITDA grew 14% to ₹308 Cr with margins at 16%, although reported PAT of ₹133 Cr was impacted by a one-time ₹42 Cr provision for labor code changes. The company maintained high R&D investment at 9% of revenue and is preparing for the launch of PivyaTM in the US market during Q4. Core segments like India Branded and US Generics showed modest growth of 6% each.
Key Highlights
Revenue from operations increased 11% YoY to ₹1,876 Cr with EBITDA rising 14% to ₹308 Cr.
Ex-US International Generics business outperformed with 36% growth, reaching ₹406 Cr.
Reported PAT stood at ₹133 Cr after accounting for a ₹42 Cr one-time provision for employee benefits.
R&D expenditure remains significant at 9% of revenue to support a pipeline of 232 cumulative ANDA approvals.
India Branded Business grew 6% to ₹652 Cr, supported by Gynaecology and Ophthalmology segments.
💼 Action for Investors
Investors should look past the one-time labor provision and focus on the strong momentum in international markets and the upcoming branded product launch in the US. The stock remains a solid play on diversified pharmaceutical growth with a healthy R&D pipeline.
Alembic Pharma Q3 FY26: International Revenue Up 17% YoY to ₹954 Cr, Animal Health Grows 22%
Alembic Pharmaceuticals reported a steady Q3 FY26 with total international generic sales growing 17% YoY to ₹954 crore, driven by strong performance in Australia (65%) and Canada (32%). The US market saw a modest 6% growth to ₹553 crore, supported by new launches like Sacubitril Valsartan. Domestic branded formulations grew 6% YoY to ₹652 crore, with the Animal Health segment showing robust growth of 22%. The company continues its R&D momentum with 5 ANDA filings YTD and 7 launches planned for Q4 FY26.
Key Highlights
International Generics revenue grew 17% YoY to ₹954 Cr, with Australia and EROW segments leading growth at 65% and 36% respectively.
US Direct sales reached ₹478 Cr, a 7% YoY increase, aided by new product launches like Ticagrelor and Metoprolol.
Domestic Branded Formulations grew 6% YoY to ₹652 Cr, significantly bolstered by a 22% surge in the Animal Health business.
API business remained relatively flat with 2% YoY growth, totaling ₹263 Cr for the quarter.
Strong R&D pipeline with 212 cumulative final ANDA approvals and 7 new products planned for launch in Q4 FY26.
💼 Action for Investors
Investors should monitor the ramp-up of new US launches and the continued outperformance of the Animal Health segment. The steady growth in EROW markets provides a good hedge against US pricing pressures.
Alembic Pharma Q3 FY26: Revenue Grows 11% YoY to ₹1,876 Cr; PAT Impacted by Exceptional Item
Alembic Pharmaceuticals reported a steady 10.8% year-on-year growth in consolidated revenue to ₹1,876.31 crore for the quarter ended December 31, 2025. Reported net profit for the quarter stood at ₹132.97 crore, a slight decline from ₹138.42 crore in the previous year, primarily due to a one-time exceptional charge of ₹42.23 crore related to new Labour Code provisions. Excluding this exceptional item, the Profit Before Tax (PBT) showed robust growth of 14.6% YoY, reaching ₹203.73 crore. The company also announced the transition of Mr. Rajkumar Baheti to a Non-Executive Director role effective April 2026.
Key Highlights
Consolidated Revenue from Operations increased 10.8% YoY to ₹1,876.31 crore.
Profit Before Tax (before exceptional items) grew 14.6% YoY to ₹203.73 crore.
Net Profit after tax stood at ₹132.97 crore, impacted by a ₹42.23 crore one-time provision for labour code compliance.
Operating Margin (EBITDA before exceptional items) was reported at 16.42% for the quarter.
Debt-to-Equity ratio remains stable and healthy at 0.25x as of December 31, 2025.
💼 Action for Investors
Investors should look past the reported PAT decline as it was caused by a non-recurring regulatory provision; the core operational PBT growth of 14.6% is a better indicator of performance. The company remains a steady hold given its consistent revenue growth and strong balance sheet.
Alembic Pharma Q3 Revenue Up 11% YoY to ₹1,876 Cr; PAT Impacted by ₹42 Cr Exceptional Item
Alembic Pharmaceuticals reported a 10.8% YoY growth in consolidated revenue for Q3 FY26, reaching ₹1,876.31 crore. However, Net Profit for the quarter declined slightly to ₹132.97 crore from ₹138.42 crore in the previous year, primarily due to a one-time exceptional charge of ₹42.23 crore related to the new Labour Code provisions. On a nine-month basis, the company performed better with revenue growing 12% to ₹5,497.18 crore. The board also approved the appointment of Mr. Rajkumar Baheti as a Non-Executive Director effective April 2026.
Key Highlights
Consolidated Revenue from Operations increased 10.8% YoY to ₹1,876.31 crore.
Net Profit after non-controlling interests stood at ₹132.97 crore, down 3.9% YoY due to exceptional items.
A one-time exceptional expense of ₹42.23 crore was recognized for gratuity and wage revisions under new Labour Codes.
Operating Margin (EBITDA before exceptional items) for the quarter was 16.42%.
Debt-Equity ratio remains healthy at 0.25x with a Net Worth of ₹5,463.32 crore.
💼 Action for Investors
Investors should look past the one-time labour code expense to the steady 11% top-line growth, though the sequential decline in margins requires monitoring. The stock remains a hold for those focused on long-term pharmaceutical sector recovery.
Alembic Pharma Receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion
Alembic Pharmaceuticals has secured final USFDA approval for Difluprednate Ophthalmic Emulsion, 0.05%, which is a generic version of Sandoz's Durezol. The product is used for treating inflammation and pain after ocular surgery and for endogenous anterior uveitis. This approval marks a continued expansion of the company's US product portfolio. With this addition, Alembic now holds a cumulative total of 233 USFDA approvals, including 213 final approvals.
Key Highlights
Received final USFDA approval for Difluprednate Ophthalmic Emulsion, 0.05%
Product is therapeutically equivalent to the reference listed drug Durezol by Sandoz Inc.
Indicated for ocular surgery inflammation and endogenous anterior uveitis
Company's cumulative USFDA approvals reach 233 (213 final and 20 tentative)
💼 Action for Investors
Investors should monitor the commercial launch and market share capture of this product in the US ophthalmic market. The steady stream of USFDA approvals remains a key driver for the company's international revenue growth.
Alembic Pharma Receives USFDA Tentative Approval for Bosutinib Tablets (400 mg)
Alembic Pharmaceuticals has received tentative approval from the USFDA for its Bosutinib Tablets, 400 mg, which is used to treat chronic myelogenous leukemia (CML). This strength adds to the company's existing final approvals for the 100 mg and 500 mg versions of the same drug. The market size for the 400 mg strength is estimated at approximately US$ 251 million for the twelve months ending September 2025. This approval brings Alembic's total USFDA ANDA count to 232, including 212 final and 20 tentative approvals.
Key Highlights
Received USFDA tentative approval for Bosutinib Tablets, 400 mg strength
Estimated market size for the 400 mg strength is US$ 251 million as of September 2025
Company already holds final approvals for 100 mg and 500 mg strengths of the same drug
Cumulative USFDA approvals reach 232 ANDAs, including 212 final approvals
The drug is a therapeutic equivalent to the reference listed drug Bosulif by PF Prism C.V.
💼 Action for Investors
Investors should monitor the transition from tentative to final approval, which will allow for commercial launch in the US market. This development strengthens Alembic's oncology portfolio in the high-value US generic space.
Alembic Pharma Receives USFDA Approval for Travoprost Ophthalmic Solution ($61M Market)
Alembic Pharmaceuticals has received final USFDA approval for Travoprost Ophthalmic Solution, a generic version of Sandoz's Travatan Z. The product is used to treat elevated intraocular pressure in patients with glaucoma or ocular hypertension. This approval targets a US market size estimated at $61 million for the 12 months ending September 2025. This milestone brings Alembic's cumulative USFDA approvals to 232, including 212 final approvals.
Key Highlights
Final USFDA approval for Travoprost Ophthalmic Solution USP, 0.004%.
Targets an estimated annual US market size of $61 million per IQVIA data.
Cumulative USFDA approvals reached 232 (212 final and 20 tentative).
Therapeutically equivalent to the reference listed drug Travatan Z by Sandoz Inc.
💼 Action for Investors
Investors should view this as a positive expansion of Alembic's US portfolio. Monitor the company's execution in capturing market share within this $61 million niche segment.
APLLTD Receives USFDA Final Approval for Loteprednol Etabonate Suspension
Alembic Pharmaceuticals Limited (APLLTD) has received USFDA final approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%. This approval allows Alembic to market a generic version of Zylet Ophthalmic Suspension. Alembic was granted Competitive Generic Therapy (CGT) designation and is eligible for 180 days of CGT exclusivity upon commercialization. This brings Alembic's cumulative ANDA approvals to 231, comprising 211 final approvals and 20 tentative approvals.
Key Highlights
Received USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
ANDA is therapeutically equivalent to Zylet Ophthalmic Suspension, 0.5%/0.3%
Granted Competitive Generic Therapy (CGT) designation
Eligible for 180 days of CGT exclusivity upon commercialization
Alembic has a cumulative total of 231 ANDA approvals from USFDA
💼 Action for Investors
This approval is a positive sign for Alembic, potentially increasing revenue through generic drug sales. Investors should monitor the commercialization and market share gains from this product.